Skip to main content
. 2021 Dec 30;29(1):163–172. doi: 10.3390/curroncol29010015

Table 4.

Patient characteristics, course of treatment, and treatment outcomes.

Case Age Sex PS Histology Prior Therapy Post Therapy Volume of Effusion (mL) Duration of Drainage (Days) Number of Intrapericardial Doses of CBDCA Administered Discharge from Hospital Response Survival after Intrapericardial Infusion (Days)
1 76 M 4 SQ None None 1235 15 1 No NE 10
2 64 M 3 SCLC CBDCA + VP-16 → CBDCA + CPT-11 None 3510 15 2 No NE 11
3 69 M 3 Large None VNR 1720 10 1 Yes CR 150
4 55 F 2 AD CDDP + GEM → CBDCA + PTX → DTX → GEF GEF 550 8 1 Yes CR 110
5 64 M 3 AD None CBDCA + PTX → DTX → GEF 900 7 1 Yes CR 313
6 48 F 3 AD DTX + GEM → GEF None 350 4 1 Yes PR 188
7 70 M 3 AD CBDCA + PTX→ DTX + S1 None 1200 3 1 Yes Failure 46
8 42 M 2 SCLC CBDCA + VP-16 + TRT → CBDCA + CPT-11 None 860 8 2 No CR 31
9 63 M 2 SCLC CBDCA + VP-16 + TRT → AMR → CBDCA + CPT-11 None 1400 4 1 No NE 20
10 63 M 3 AD CBDCA + PTX → DTX None 450 5 1 Yes CR 145
11 67 F 2 AD CDDP + S1 + Bev → TRT → CRZ PEM → ALC 540 3 1 Yes PR 2435 a
12 51 M 3 SQ CBDCA + PTX + TRT → DTX → S1 → ERL → GEM None 3160 7 1 Yes CR 53
13 50 F 3 AD CBDCA + DTX + Bev → PEM → ERL None 640 4 1 Yes CR 99
14 44 M 2 AD CBDCA + PTX + TRT → CDDP + VNR None 11,380 85 3 No Failure 66
15 59 F 3 AD None CBDCA + PTX 450 10 1 Yes CR 69
16 59 F 3 AD CBDCA + DTX + Bev DTX 1285 10 1 Yes CR 158
17 60 F 2 AD None CBDCA + PTX → PEM 1450 9 1 No CR 71
18 58 M 3 AD CDDP + S1 → DTX None 1555 9 1 No NE 24
19 46 M 2 AD None None 1270 14 1 No NE 27
20 67 M 1 SQ CBDCA + PTX + TRT None 880 9 1 Yes PR 136
21 69 M 3 SQ CBDCA + PTX None 2050 11 1 Yes CR 245

a Alive at cut-off date. Abbreviations: PS, performance status; SQ, squamous cell carcinoma; SCLC, small cell lung cancer; Large, large cell carcinoma; AD, adenocarcinoma; CBDCA, carboplatin; VP-16, etoposide; CPT-11, irinotecan; CDDP, cisplatin; GEM, gemcitabine; PTX, paclitaxel; DTX, docetaxel; GEF, gefitinib; TRT, thoracic radiotherapy; AMR, amrubicin; Bev, bevacizumab; CRZ, crizotinib; ERL, erlotinib; PEM, pemetrexed; VNR, vinorelbine; ALC, alectinib; NE, not evaluated; CR, complete response; PR, partial response.